Summary:
A 52-week, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of roflumilast 500 μg on exacerbation rate in subjects with chronic obstructive pulmonary disease (copd) treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (laba/ics).
Qualified Participants Must:
•
Have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD).
•
Be 40 years of age or older.
•
Be a former smoker
•
Be on Advair or Symbicort for 3 months prior to visit 1
•
Have had 2 documented COPD exacerbations treated with antibiotics or steroids.
Qualified Participants May Receive:
All study related medication and care at no cost. Eligible participants will be compensated for time and travel.